VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
Bristol-Myers Squibb Company vs L3Harris Technologies, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Bristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisL3Harris Technologies, Inc.
LHX · NYSE
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into L3Harris Technologies, Inc.'s moat claims, evidence, and risks.
View LHX analysisComparison highlights
- Moat score gap: L3Harris Technologies, Inc. leads (72 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)); L3Harris Technologies, Inc. has 4 segments (31.9% in Space & Airborne Systems).
- Moat breadth: Bristol-Myers Squibb Company has 4 moat types across 3 domains; L3Harris Technologies, Inc. has 8 across 3.
Primary market context
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
L3Harris Technologies, Inc.
Space & Airborne Systems
Defense & intelligence space and airborne mission systems (payloads, sensors, avionics, mission networks)
Global (U.S.-centric demand)
Government defense/intelligence agencies, prime contractors, and allied governments
Prime contractor / subsystem integrator
31.9%
Side-by-side metrics
Moat coverage
Shared moat types
Bristol-Myers Squibb Company strengths
L3Harris Technologies, Inc. strengths
Segment mix
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
L3Harris Technologies, Inc. segments
Full profile >Space & Airborne Systems
Oligopoly
Integrated Mission Systems
Oligopoly
Communication Systems
Oligopoly
Aerojet Rocketdyne
Duopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.